SCHEMBL6915787

SCHEMBL6915787

COC(=O)c1ccc(C(=C(C)C)c2cc3c(cc2OCc2ccccc2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 8/20 0.52
HNF4A P41235 3/20 0.49
CYP3A4 P08684 3/20 0.48
LMNA P02545 2/20 0.46
HPGD P15428 1/20 0.46
RXRB P28702 1/20 0.46
CYP26A1 O43174 2/20 0.45
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SMPD1 P17405 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LNPEP Q9UIQ6 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6915796 0.90 RXRA (0.65) RXRAHNF4ARXRB
SCHEMBL6917161 0.80 MAOB (0.55) RXRAHNF4ARXRBMAPTL3MBTL1
SCHEMBL8890601 0.79 RARB (0.45) RXRACYP3A4LMNAHPGDRXRB
SCHEMBL6910117 0.79 RXRA (0.55) RXRAHNF4ACYP3A4LMNARXRB
SCHEMBL6915899 0.78 RXRA (0.76) RXRAHNF4ARXRB
SCHEMBL6915315 0.77 RXRA (0.53) RXRAHNF4ACYP3A4LMNARXRB
SCHEMBL7173098 0.77 RXRA (0.57) RXRAHNF4ARXRBMAPTRAB9A
SCHEMBL7421190 0.76 RXRA (0.72) RXRACYP3A4LMNARXRBCYP26A1
SCHEMBL7174242 0.76 RXRA (0.60) RXRAHNF4ARXRBSMPD1HDAC1
SCHEMBL6918873 0.75 RXRA (0.45) RXRAHNF4ARXRBCYP26A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019072-A1 Dimer-selective RXR modulators and methods for their use CANAN-KOCH STACIE (US) 2004-01-29 US disclosed
EP-1336600-A2 Dimer-selective RXR modulators and methods for their use LIGAND PHARMACEUTICALS INCORPORATED (US) 2003-08-20 EP disclosed
US-6545049-B1 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof LIGAND PHARMACEUTICALS INCORPORATED 2003-04-08 US disclosed
EP-0873295-A1 DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE LIGAND PHARMACEUTICALS, INC. (US) 1998-10-28 EP disclosed
WO-1997012853-A1 DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019072-A1 Dimer-selective RXR modulators and methods for their use RXRG, RXRB, RXRA RXRA 3/4885HNF4A 118/4885CYP3A4 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.